Humanwell Healthcare (Group) Co.,Ltd. (HUMANWELL HEALTHCARE (GROUP) CO) aktie

Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection, an analgesic drug for combined anesthesia; remifentanil hydrochloride injection for induction of general anesthesia and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for patients who require opioid analgesia; nabuphine hydrochloride injection for use as an analgesic for anesthesia induction; alfentanil hydrochloride injection, a narcotic analgesic; remizaren besylate injection for sedation and anesthesia during non-endotracheal intubation surgery; and mifepristone preparations for pregnancy prevention or termination. It also provides zuka wood particles for colds; compound muniziqi granules to treat skin and gynecologicalconditions; urokinase injection for thromboembolic diseases; and neomycin sulfate API for the prevention and treatment of intestinal diseases in animals. In addition, the company offers progesterone, estrogen, androgen, cortical hormone, and other API products; steroid hormone products; natural plant-based medicines; central nervous system drugs; animal medicine; narcotics; and Uyghur medicine products. Further, it is involved in the production of veterinary drugs, feed additive, medical devices, and agricultural products; technical development, exchange, and transfer; leasing of medical devices; conference, exhibition, inspection, and testing; property management; pharmaceutical contract manufacturing; cleaning, washing, and disinfection; warehousing and logistics; investment management and consulting services; and production of health foods. The company was formerly known as Wuhan Humanwell Healthcare (Group) Co., Ltd. and changed its name to Humanwell Healthcare (Group) Co.,Ltd. in March 2013. Humanwell Healthcare (Group) Co.,Ltd. was founded in 1988 and is based in Wuhan, China.